TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of PCOS (Polycystic Ovary Syndrome)in Morbidly Obese Women - A Randomized Controlled Prospective Dietary Intervention Study
Brief Summary: This study has two phases:

1. In phase 1 of the study (8 weeks),the effect of two different low calorie diets on manifestations of PCOS, including risk factors for the metabolic syndrome and cardiovascular risk profile will be compared.
2. In phase 2 the long term effect (next 44 weeks) on sustained weight-loss and the above mentioned parameters will be compared and evaluated.


Options:
A: Arm Label: Low-frequency electro-acupuncture; Type: EXPERIMENTAL; Interventions: Procedure: Electroacupuncture | Arm Label: Physical exercise; Type: EXPERIMENTAL; Interventions: Procedure: Physical exercise | Arm Label: Untreated control; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Untreated control | Intervention Type: PROCEDURE; Name: Electroacupuncture; Assigned to Arm(s): Low-frequency electro-acupuncture | Intervention Type: PROCEDURE; Name: Physical exercise; Assigned to Arm(s): Physical exercise | Intervention Type: PROCEDURE; Name: Untreated control; Assigned to Arm(s): Untreated control
B: Arm Label: Lifestyle intervention; Type: ACTIVE_COMPARATOR; Interventions: Drug: Orlistat/Meal Replacement/Lifestyle Modification | Arm Label: Oral Contraceptives (OCP); Type: ACTIVE_COMPARATOR; Interventions: Drug: Loestrin 1/20 | Arm Label: Lifestyle/OCP Combined; Type: ACTIVE_COMPARATOR; Interventions: Drug: Combination of treatments | Intervention Type: DRUG; Name: Orlistat/Meal Replacement/Lifestyle Modification; Assigned to Arm(s): Lifestyle intervention | Intervention Type: DRUG; Name: Loestrin 1/20; Assigned to Arm(s): Oral Contraceptives (OCP) | Intervention Type: DRUG; Name: Combination of treatments; Assigned to Arm(s): Lifestyle/OCP Combined
C: Intervention Type: BEHAVIORAL; Name: Structured exercise training; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Hypocaloric hyperproteic diet; Assigned to Arm(s): N/A
D: Arm Label: Crispbread; Type: EXPERIMENTAL; Interventions: Behavioral: Crispbread | Arm Label: Liquid meal replacement; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Crispbread | Intervention Type: BEHAVIORAL; Name: Crispbread; Assigned to Arm(s): Crispbread, Liquid meal replacement

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of PCOS (Polycystic Ovary Syndrome)in Morbidly Obese Women - A Randomized Controlled Prospective Dietary Intervention Study
Brief Summary: This study has two phases:

1. In phase 1 of the study (8 weeks),the effect of two different low calorie diets on manifestations of PCOS, including risk factors for the metabolic syndrome and cardiovascular risk profile will be compared.
2. In phase 2 the long term effect (next 44 weeks) on sustained weight-loss and the above mentioned parameters will be compared and evaluated.


Options:
A: Arm Label: Crispbread; Type: EXPERIMENTAL; Interventions: Behavioral: Crispbread | Arm Label: Liquid meal replacement; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Crispbread | Intervention Type: BEHAVIORAL; Name: Crispbread; Assigned to Arm(s): Crispbread, Liquid meal replacement
B: Arm Label: Letrozole -Berberine; Type: EXPERIMENTAL; Interventions: Drug: Letrozole -Berberine | Arm Label: Letrozole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Letrozole | Arm Label: Berberine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Berberine | Intervention Type: DRUG; Name: Letrozole -Berberine; Assigned to Arm(s): Letrozole -Berberine | Intervention Type: DRUG; Name: Letrozole; Assigned to Arm(s): Letrozole | Intervention Type: DRUG; Name: Berberine; Assigned to Arm(s): Berberine
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clomiphene citrate | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Letrozole | Intervention Type: DRUG; Name: Clomiphene citrate; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Letrozole; Assigned to Arm(s): B
D: Arm Label: Berberine; Type: EXPERIMENTAL; Interventions: Drug: Berberine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Berberine; Assigned to Arm(s): Berberine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy, Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects
Brief Summary: This is a multicenter study in which women are planned to receive either the HPV vaccine or control. Study participation will last approximately 72 months and involves a total of thirteen or fourteen scheduled visits.

Originally, the study was planned for 24 months. It was then extended for 2 more years with 4 additional visits (study end at Month 48).

The protocol posting has been updated as the study was extended by additional 2 years with two or three additional visits (study end at Month 72) for subjects who consent to participate in the extension.


Options:
A: Arm Label: V503; Type: EXPERIMENTAL; Interventions: Biological: V503 | Arm Label: GARDASIL; Type: ACTIVE_COMPARATOR; Interventions: Biological: GARDASIL | Intervention Type: BIOLOGICAL; Name: V503; Assigned to Arm(s): V503 | Intervention Type: BIOLOGICAL; Name: GARDASIL; Assigned to Arm(s): GARDASIL
B: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine | Arm Label: Havrix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: hepatitis A inactivated virus vaccine | Intervention Type: BIOLOGICAL; Name: human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: hepatitis A inactivated virus vaccine; Assigned to Arm(s): Havrix Group
C: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: HPV GSK 580299 vaccine | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo control | Intervention Type: BIOLOGICAL; Name: HPV GSK 580299 vaccine; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Placebo control; Assigned to Arm(s): Placebo Group
D: Arm Label: Cervarix 1/Placebo Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Drug: Placebo | Arm Label: Cervarix 1/Placebo/Cervarix 1 Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Drug: Placebo | Arm Label: Cervarix 2/Placebo/Cervarix 2 Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Drug: Placebo | Arm Label: Cervarix 2 Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix 1/Placebo Group, Cervarix 1/Placebo/Cervarix 1 Group, Cervarix 2 Group, Cervarix 2/Placebo/Cervarix 2 Group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cervarix 1/Placebo Group, Cervarix 1/Placebo/Cervarix 1 Group, Cervarix 2/Placebo/Cervarix 2 Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy, Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects
Brief Summary: This is a multicenter study in which women are planned to receive either the HPV vaccine or control. Study participation will last approximately 72 months and involves a total of thirteen or fourteen scheduled visits.

Originally, the study was planned for 24 months. It was then extended for 2 more years with 4 additional visits (study end at Month 48).

The protocol posting has been updated as the study was extended by additional 2 years with two or three additional visits (study end at Month 72) for subjects who consent to participate in the extension.


Options:
A: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: HPV GSK 580299 vaccine | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo control | Intervention Type: BIOLOGICAL; Name: HPV GSK 580299 vaccine; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Placebo control; Assigned to Arm(s): Placebo Group
B: Arm Label: HIV+/Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Arm Label: HIV+/Aluminium Hydroxide Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Placebo Control | Arm Label: HIV-/Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): HIV+/Cervarix Group, HIV-/Cervarix Group | Intervention Type: BIOLOGICAL; Name: Placebo Control; Assigned to Arm(s): HIV+/Aluminium Hydroxide Group
C: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV vaccine (GSK1674330A) | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV vaccine (GSK1674330A) | Arm Label: Group C; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV vaccine (GSK1674330A) | Arm Label: Group D; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV vaccine (GSK1674330A) | Arm Label: Group E; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV vaccine (GSK1674330A) | Arm Label: Group F; Type: ACTIVE_COMPARATOR; Interventions: Biological: Cervarix TM | Intervention Type: BIOLOGICAL; Name: GSK Biologicals' HPV vaccine (GSK1674330A); Assigned to Arm(s): Group A, Group B, Group C, Group D, Group E | Intervention Type: BIOLOGICAL; Name: Cervarix TM; Assigned to Arm(s): Group F
D: Arm Label: 12 months; Type: EXPERIMENTAL; Interventions: Biological: quadrivalent human papillomavirus vaccine | Arm Label: 6 month; Type: ACTIVE_COMPARATOR; Interventions: Biological: quadrivalent human papillomavirus vaccine | Intervention Type: BIOLOGICAL; Name: quadrivalent human papillomavirus vaccine; Assigned to Arm(s): 12 months | Intervention Type: BIOLOGICAL; Name: quadrivalent human papillomavirus vaccine; Assigned to Arm(s): 6 month

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Exclusion of the Left Atrial Appendage With the AtriClip LAA Exclusion Device in Patients Undergoing Concomitant Cardiac Surgery
Brief Summary: Prospective, non-randomized trial to evaluate the safety and efficacy of the LAA Exclusion Device (Clip) for the exclusion of the LAA via epicardial tissue approximation.


Options:
A: Arm Label: AtriCure LAA Exclusion System; Type: EXPERIMENTAL; Interventions: Device: AtriCure LAA Exclusion System | Intervention Type: DEVICE; Name: AtriCure LAA Exclusion System; Assigned to Arm(s): AtriCure LAA Exclusion System
B: Arm Label: MVS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: MVS | Arm Label: Ablation; Type: EXPERIMENTAL; Interventions: Procedure: MVS, Device: Ablation | Intervention Type: PROCEDURE; Name: MVS; Assigned to Arm(s): Ablation, MVS | Intervention Type: DEVICE; Name: Ablation; Assigned to Arm(s): Ablation
C: Arm Label: Add-on arrhythmia surgery; Type: EXPERIMENTAL; Interventions: Procedure: Pulmonary vein isolation using microwave energy | Intervention Type: PROCEDURE; Name: Pulmonary vein isolation using microwave energy; Assigned to Arm(s): Add-on arrhythmia surgery
D: Arm Label: LAA Clip; Type: EXPERIMENTAL; Interventions: Device: AtriCure LAA Exclusion System | Intervention Type: DEVICE; Name: AtriCure LAA Exclusion System; Assigned to Arm(s): LAA Clip

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Autologous Serum Efficacy Study in Patients With Severe Dry Eye
Brief Summary: The purpose of this study is to compare the reduction in symptomatology of patients with severe dry eye treated with autologous serum and conventional artificial tears.


Options:
A: Arm Label: Normal; Type: N/A; Interventions: N/A | Arm Label: Dry Eye Disease; Type: N/A; Interventions: N/A
B: Arm Label: Severe dry eye; Type: EXPERIMENTAL; Interventions: Drug: 0.02% Fm, SH, Drug: 0.02% Fm, SH, 0.05% CsA, Other: 0.02% Fm, SH, tBCL, Drug: 0.02% Fm, SH, AS | Intervention Type: DRUG; Name: 0.02% Fm, SH; Assigned to Arm(s): Severe dry eye | Intervention Type: DRUG; Name: 0.02% Fm, SH, 0.05% CsA; Assigned to Arm(s): Severe dry eye | Intervention Type: OTHER; Name: 0.02% Fm, SH, tBCL; Assigned to Arm(s): Severe dry eye | Intervention Type: DRUG; Name: 0.02% Fm, SH, AS; Assigned to Arm(s): Severe dry eye
C: Arm Label: Autologous serum -Systane; Type: OTHER; Interventions: Drug: Autologous serum - Systane | Arm Label: Systane- Autologous serum; Type: OTHER; Interventions: Drug: Systane - Autologous serum | Intervention Type: DRUG; Name: Autologous serum - Systane; Assigned to Arm(s): Autologous serum -Systane | Intervention Type: DRUG; Name: Systane - Autologous serum; Assigned to Arm(s): Systane- Autologous serum
D: Arm Label: UCB eyedrops, single arm; Type: N/A; Interventions: Other: UCS eyedrops | Intervention Type: OTHER; Name: UCS eyedrops; Assigned to Arm(s): UCB eyedrops, single arm

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nasal Intermittent Positive Pressure Ventilation In Newborn Infants With Respiratory Distress Syndrome
Brief Summary: The submitted trial is the first prospective, randomized trial comparing nasal intermittent positive pressure ventilation(NIPPV) vs nCPAP in newborn infants with respiratory distress syndrome.


Options:
A: Arm Label: CPAP ventilation mode; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CPAP ventilation mode | Arm Label: NIPPV ventilation mode; Type: EXPERIMENTAL; Interventions: Procedure: NIPPV ventilation mode | Intervention Type: PROCEDURE; Name: CPAP ventilation mode; Assigned to Arm(s): CPAP ventilation mode | Intervention Type: PROCEDURE; Name: NIPPV ventilation mode; Assigned to Arm(s): NIPPV ventilation mode
B: Arm Label: NIPPV; Type: ACTIVE_COMPARATOR; Interventions: Device: NIPPV | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Device: NIPPV | Intervention Type: DEVICE; Name: NIPPV; Assigned to Arm(s): Control, NIPPV | Intervention Type: DEVICE; Name: NIPPV; Assigned to Arm(s): Control, NIPPV | Intervention Type: DEVICE; Name: NIPPV; Assigned to Arm(s): Control, NIPPV
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Device: NIPPV | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Device: nCPAP | Intervention Type: DEVICE; Name: nCPAP; Assigned to Arm(s): B | Intervention Type: DEVICE; Name: NIPPV; Assigned to Arm(s): A
D: Arm Label: NCPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: nasal intermittent positive pressure ventilation | Arm Label: NIPPV; Type: EXPERIMENTAL; Interventions: Device: nasal intermittent positive pressure ventilation | Intervention Type: DEVICE; Name: nasal intermittent positive pressure ventilation; Assigned to Arm(s): NCPAP, NIPPV

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nasal Intermittent Positive Pressure Ventilation In Newborn Infants With Respiratory Distress Syndrome
Brief Summary: The submitted trial is the first prospective, randomized trial comparing nasal intermittent positive pressure ventilation(NIPPV) vs nCPAP in newborn infants with respiratory distress syndrome.


Options:
A: Arm Label: CPAP ventilation mode; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CPAP ventilation mode | Arm Label: NIPPV ventilation mode; Type: EXPERIMENTAL; Interventions: Procedure: NIPPV ventilation mode | Intervention Type: PROCEDURE; Name: CPAP ventilation mode; Assigned to Arm(s): CPAP ventilation mode | Intervention Type: PROCEDURE; Name: NIPPV ventilation mode; Assigned to Arm(s): NIPPV ventilation mode
B: Arm Label: Nasal Continuous Positive Airway Pressure (CPAP); Type: ACTIVE_COMPARATOR; Interventions: Device: Nasal CPAP (SLE) | Arm Label: Nasal Intermittent Mandatory Ventilation (IMV); Type: ACTIVE_COMPARATOR; Interventions: Device: Nasal IMV (SLE) | Intervention Type: DEVICE; Name: Nasal CPAP (SLE); Assigned to Arm(s): Nasal Continuous Positive Airway Pressure (CPAP) | Intervention Type: DEVICE; Name: Nasal IMV (SLE); Assigned to Arm(s): Nasal Intermittent Mandatory Ventilation (IMV)
C: Arm Label: NIPPV; Type: ACTIVE_COMPARATOR; Interventions: Device: NIPPV | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Device: NIPPV | Intervention Type: DEVICE; Name: NIPPV; Assigned to Arm(s): Control, NIPPV | Intervention Type: DEVICE; Name: NIPPV; Assigned to Arm(s): Control, NIPPV | Intervention Type: DEVICE; Name: NIPPV; Assigned to Arm(s): Control, NIPPV
D: Arm Label: BP-NCPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: BP-NCPAP | Arm Label: NIHFV; Type: EXPERIMENTAL; Interventions: Device: NIHFV | Intervention Type: DEVICE; Name: BP-NCPAP; Assigned to Arm(s): BP-NCPAP | Intervention Type: DEVICE; Name: NIHFV; Assigned to Arm(s): NIHFV

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nasal Intermittent Positive Pressure Ventilation In Newborn Infants With Respiratory Distress Syndrome
Brief Summary: The submitted trial is the first prospective, randomized trial comparing nasal intermittent positive pressure ventilation(NIPPV) vs nCPAP in newborn infants with respiratory distress syndrome.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Device: NIPPV | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Device: nCPAP | Intervention Type: DEVICE; Name: nCPAP; Assigned to Arm(s): B | Intervention Type: DEVICE; Name: NIPPV; Assigned to Arm(s): A
B: Arm Label: NCPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: nasal intermittent positive pressure ventilation | Arm Label: NIPPV; Type: EXPERIMENTAL; Interventions: Device: nasal intermittent positive pressure ventilation | Intervention Type: DEVICE; Name: nasal intermittent positive pressure ventilation; Assigned to Arm(s): NCPAP, NIPPV
C: Arm Label: NSIPPV group; Type: ACTIVE_COMPARATOR; Interventions: Device: NSIPPV | Arm Label: BiPAP group; Type: ACTIVE_COMPARATOR; Interventions: Device: BiPAP | Intervention Type: DEVICE; Name: NSIPPV; Assigned to Arm(s): NSIPPV group | Intervention Type: DEVICE; Name: BiPAP; Assigned to Arm(s): BiPAP group
D: Arm Label: NIPPV; Type: ACTIVE_COMPARATOR; Interventions: Device: NIPPV | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Device: NIPPV | Intervention Type: DEVICE; Name: NIPPV; Assigned to Arm(s): Control, NIPPV | Intervention Type: DEVICE; Name: NIPPV; Assigned to Arm(s): Control, NIPPV | Intervention Type: DEVICE; Name: NIPPV; Assigned to Arm(s): Control, NIPPV

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of TNF-blocker Injections Spacing on Rheumatoid Arthritis Inflammatory Activity in Patients in Clinical Remission or Low Disease Activity
Brief Summary: Remission is nowadays the recommended therapeutic objective in rheumatoid arthritis. Once this objective is achieved thanks to TNF-blockers, the optimal therapeutic strategy remains unclear, either therapeutic maintenance or progressive DMARD tapering (with a non quantified risk of disease flare).

STRASS is a 2-arm randomized controlled trial aiming to compare these 2 strategies (DMARD maintenance or progressive spacing of TNF-blocker injections) in terms of remission maintenance, relapse risk, safety issues and economic consequences during 18 months.

The inclusion period is 18 months, between September 2008 and February 2010.


Options:
A: Arm Label: CZP 200 mg Q2W + Methotrexate; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX) | Arm Label: CZP 200 mg Q4W + Methotrexate; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX) | Arm Label: Placebo + Methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo + Methotrexate (MTX) | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol + Methotrexate (MTX); Assigned to Arm(s): CZP 200 mg Q2W + Methotrexate, CZP 200 mg Q4W + Methotrexate | Intervention Type: BIOLOGICAL; Name: Placebo + Methotrexate (MTX); Assigned to Arm(s): Placebo + Methotrexate
B: Arm Label: Adalimumab 40 mg eow; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab | Arm Label: Adalimumab Tapering; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Arm Label: Adalimumab Withdrawal Arm; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Adalimumab 40 mg eow Rescue Arm; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Adalimumab 40 mg eow, Adalimumab 40 mg eow Rescue Arm, Adalimumab Tapering | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Adalimumab Withdrawal Arm
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
D: Arm Label: 1-M : Maintenance; Type: ACTIVE_COMPARATOR; Interventions: Drug: DMARD maintenance | Arm Label: 2 -S : Spacing of TNF-blocker injections; Type: EXPERIMENTAL; Interventions: Drug: progressive spacing of TNF-blocker injections | Intervention Type: DRUG; Name: progressive spacing of TNF-blocker injections; Assigned to Arm(s): 2 -S : Spacing of TNF-blocker injections | Intervention Type: DRUG; Name: DMARD maintenance; Assigned to Arm(s): 1-M : Maintenance

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Home Blood Pressure Telemonitoring and Case Management to Control Hypertension
Brief Summary: In this project we develop and implement an intervention to improve hypertension control in a primary care setting that takes advantage of new technology (home blood pressure telemonitoring) and team models of care (pharmacist case management). The results of the project will have important implications for future efforts to improve care provided to many of the estimated 20 million Americans with uncontrolled hypertension.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Telemonitors and pharmacy management; Type: EXPERIMENTAL; Interventions: Other: Telemonitors and pharmacy management | Intervention Type: OTHER; Name: Telemonitors and pharmacy management; Assigned to Arm(s): Telemonitors and pharmacy management
B: Arm Label: 1; Type: N/A; Interventions: Other: 1 | Arm Label: 2; Type: N/A; Interventions: Other: 2 | Intervention Type: OTHER; Name: 1; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: 2; Assigned to Arm(s): 2
C: Intervention Type: BEHAVIORAL; Name: Pharmacist intervention; Assigned to Arm(s): N/A
D: Arm Label: NMS; Type: EXPERIMENTAL; Interventions: Other: New Medicine Service | Arm Label: Current Practice; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: New Medicine Service; Assigned to Arm(s): NMS

Answer: A